Akums Drugs and Pharmaceuticals (AKUMS) Stock Overview
Manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AKUMS from our risk checks.
AKUMS Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Akums Drugs and Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹465.65 |
| 52 Week High | ₹949.00 |
| 52 Week Low | ₹405.00 |
| Beta | 0 |
| 1 Month Change | -7.31% |
| 3 Month Change | -17.46% |
| 1 Year Change | -47.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.52% |
Recent News & Updates
Major Pharma Contract And Global Expansion Will Forge Future Promise
Long-term export contract, product diversification, and international expansion are driving predictable revenue growth, profitability, and geographic risk mitigation.Concerns Surrounding Akums Drugs and Pharmaceuticals' (NSE:AKUMS) Performance
Jul 02
Recent updates
Major Pharma Contract And Global Expansion Will Forge Future Promise
Long-term export contract, product diversification, and international expansion are driving predictable revenue growth, profitability, and geographic risk mitigation.Concerns Surrounding Akums Drugs and Pharmaceuticals' (NSE:AKUMS) Performance
Jul 02Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS) Not Flying Under The Radar
May 18Shareholder Returns
| AKUMS | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -0.5% | -0.2% | 0.7% |
| 1Y | -47.4% | 7.8% | -6.8% |
Return vs Industry: AKUMS underperformed the Indian Life Sciences industry which returned 7.8% over the past year.
Return vs Market: AKUMS underperformed the Indian Market which returned -6.8% over the past year.
Price Volatility
| AKUMS volatility | |
|---|---|
| AKUMS Average Weekly Movement | 3.9% |
| Life Sciences Industry Average Movement | 5.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 7.9% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: AKUMS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: AKUMS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 7,536 | Sanjeev Jain | www.akums.in |
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology.
Akums Drugs and Pharmaceuticals Limited Fundamentals Summary
| AKUMS fundamental statistics | |
|---|---|
| Market cap | ₹71.29b |
| Earnings (TTM) | ₹3.41b |
| Revenue (TTM) | ₹41.26b |
Is AKUMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKUMS income statement (TTM) | |
|---|---|
| Revenue | ₹41.26b |
| Cost of Revenue | ₹24.85b |
| Gross Profit | ₹16.41b |
| Other Expenses | ₹12.99b |
| Earnings | ₹3.41b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 22.30 |
| Gross Margin | 39.77% |
| Net Profit Margin | 8.28% |
| Debt/Equity Ratio | 2.9% |
How did AKUMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/04 17:57 |
| End of Day Share Price | 2025/09/04 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akums Drugs and Pharmaceuticals Limited is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Ashwin Mehta | Ambit Capital |
| Prashant Nair | Ambit Capital |